Metraipolis › archive › dc_fc93ebcb50e4

Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments — Europe PMC PMID:41180903

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41180903
DOI: 10.1177/20552173251390649
License (as archived): solo-consultazione
Archived: 2026-11-08T23:44:26.975Z
SHA-256 of the archived text: afc8b11d13eacc5f06d9c9df25559e7f49f4a55f8d06b7c3d619c8043b4660b5
Stable URL of this page: https://metraipolis.com/documento/dc_fc93ebcb50e4

How to cite

Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments — Europe PMC PMID:41180903 — Europe PMC (en), https://europepmc.org/article/MED/41180903 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fc93ebcb50e4 (Metraipolis archive dc_fc93ebcb50e4, sha256 afc8b11d13eacc5f06d9c9df25559e7f49f4a55f8d06b7c3d619c8043b4660b5)

BibTeX

@misc{dcfc93ebcb50e4,
  title = {Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments — Europe PMC PMID:41180903},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41180903},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fc93ebcb50e4; sha256 afc8b11d13eacc5f06d9c9df25559e7f49f4a55f8d06b7c3d619c8043b4660b5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41180903. Agents can read the archived copy with the MCP tool read_document.